A Virtual Collection Focused on Antifungal Drug Discovery

Discovery of VU6052959/BI'7927: A Selective mGlu3 Positive Allosteric Modulator (PAM) from an Orthogonal Benzoxazine Chemotype.

ACS medicinal chemistry letters·2026

Discovery of VU6081679, a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor 8 with Efficacy in a Preclinical Model of Parkinson's Disease.

ACS chemical neuroscience·2026

Optimization of Pyrazole-Based Activators of Kv3.1.

ACS medicinal chemistry letters·2026

Discovery of VU6077564: A Selective M1 Antagonist That Promotes Neurite Outgrowth in Adult Sensory Neurons.

ACS chemical neuroscience·2026

Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.

Journal of medicinal chemistry·2026

Discovery of VU6066098: A Selective and CNS-Penetrant mGlu2 NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in Rodents.

ACS chemical neuroscience·2026

Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody-Oligonucleotide Conjugates with High Drug-to-Antibody Ratios.

Journal of medicinal chemistry·2026

Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.

Journal of medicinal chemistry·2026

Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors.

Journal of medicinal chemistry·2026

Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.

Journal of medicinal chemistry·2026

Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.

Journal of medicinal chemistry·2026

Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight.

Journal of medicinal chemistry·2026

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Archiv der Pharmazie·2026

Sequential soxhlet fractionation of Cistus ladanifer L. reveals a polarity-activity gradient: GC-MS profiling, multimechanistic bioactivity, and in silico identification of antifungal and antibacterial lead compounds.

Frontiers in chemistry·2026

Novel Benzofuran Derivatives as SARM1 Inhibitors for Treating Axonal Degeneration.

ACS medicinal chemistry letters·2026

Novel Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.

ACS medicinal chemistry letters·2026

Structure-Activity Relationship Studies Resulting in the Identification of Potent and Selective Salt-Inducible Kinase Inhibitors.

ACS medicinal chemistry letters·2026

Structural Preferences and ADMET Regulation of Fluorinated Small-Molecule Drugs.

ACS medicinal chemistry letters·2026

Related Experiment Videos

A Virtual Collection Focused on Antifungal Drug Discovery

Related Concept Videos

Discovery of VU6052959/BI'7927: A Selective mGlu3 Positive Allosteric Modulator (PAM) from an Orthogonal Benzoxazine Chemotype.

Discovery of VU6081679, a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor 8 with Efficacy in a Preclinical Model of Parkinson's Disease.

Optimization of Pyrazole-Based Activators of Kv3.1.

Discovery of VU6077564: A Selective M1 Antagonist That Promotes Neurite Outgrowth in Adult Sensory Neurons.

Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.

Discovery of VU6066098: A Selective and CNS-Penetrant mGlu2 NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in Rodents.

Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody-Oligonucleotide Conjugates with High Drug-to-Antibody Ratios.

Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.

Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors.

Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.

Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.

Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight.

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Sequential soxhlet fractionation of Cistus ladanifer L. reveals a polarity-activity gradient: GC-MS profiling, multimechanistic bioactivity, and in silico identification of antifungal and antibacterial lead compounds.

Novel Benzofuran Derivatives as SARM1 Inhibitors for Treating Axonal Degeneration.

Novel Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.

Structure-Activity Relationship Studies Resulting in the Identification of Potent and Selective Salt-Inducible Kinase Inhibitors.

Structural Preferences and ADMET Regulation of Fluorinated Small-Molecule Drugs.

Related Experiment Videos

A Virtual Collection Focused on Antifungal Drug Discovery

Related Concept Videos

Related Articles